Abstract:Glucagon-like peptide-2 (GLP-2), an intestinotrophic hormone, has drawn considerable attention worldwide due to its potential to promote intestinal development. We investigated the effects and mechanisms of GLP-2 against lipopolysaccharide (LPS)-induced intestinal inflammation and injury both in vitro and in vivo. Forty healthy piglets weaned at the age of 28 days with similar body weight (BW) were assigned to four in vivo treatments with ten piglets each: (i) nonchallenged control; (ii) LPS-challenged control; (iii) LPS + low dose GLP-2; and (iv) LPS + high dose GLP-2. Piglets were subcutaneously injected with phosphate-buffered saline supplemented with GLP-2 at doses of 0, 0, 2, and 10 nmol/kg BW per day for seven consecutive days. The piglets were challenged with an intraperitoneal injection with 100 mu g/kg LPS on day 14 to induce intestinal damage. After that, the gene and protein expression levels of representative tight junction proteins and myosin light-chain kinase (MLCK)/phosphorylated myosin light chain (pMLC), as well as proinflammatory cytokine levels were determined using quantitative reverse transcription polymerase chain reaction, western blot, and enzyme-linked immunosorbent assay methods. A high dose of GLP-2 pretreatment increased intestinal permeability by downregulating and redistributing tight junction proteins (p < .05), for example, zona occluden-1 (ZO-1) and occludin. GLP-2 decreased the transcription of proinflammatory cytokines genes including interleukin-1 beta (IL-1 beta), IL-6, IL-8, and tumor necrosis factor-alpha in small intestines (p < .05). GLP-2 prevented the LPS-induced increase in the expression of MLCK dose-dependently and the increase in pMLC levels in the duodenum, jejunum, and ileum. To assess further the protective effect of GLP-2 on LPS-induced intestinal barrier injury after weaning and its possible mechanism, an in vitro intestinal epithelial barrier model was established with IPEC-J2 monolayers and treated with 100 mu g/ml LPS with or without 1 x 10(-8) mol/L GLP-2 pretreatment. The in vitro analysis included control, LPS, and GLP-2 + LPS treatments. GLP-2 treatment alleviated the destructive effect of LPS on barrier permeability by restoring the expression and ultrastructure of ZO-1 and occludin (p < .05). In addition, GLP-2 reversed the LPS-induced MLCK hyperexpression and pMLC hyperphosphorylation (p < .05). Taken together, our findings revealed a mechanism by which GLP-2 alleviated LPS-challenged intestinal barrier injury and inflammation in weaned piglets and IPEC-J2 cells via the MLCK/pMLC signaling pathway.

Glucagon-Like Peptide-2 Modulates Enteric Paneth Cells Immune Response and Alleviates Gut Inflammation During Intravenous Fluid Infusion in Mice With a Central Catheter

Glucagon-like Peptide-2 Improves Intestinal Immune Function and Diminishes Bacterial Translocation in a Mouse Model of Parenteral Nutrition

Glp-2 Prevents Intestinal Mucosal Atrophy And Improves Tissue Antioxidant Capacity In A Mouse Model Of Total Parenteral Nutrition

[Effect of Glucagon-Like Peptide 2 on the Intestinal Mucosal Immunity and Correlative Cytokines in Mice with Gut Ischemia/reperfusion Injury].

GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/- Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR Signaling

The protective and anti-inflammatory effects of a modified glucagon-like peptide-2 dimer in inflammatory bowel disease.

The protective effect of oral colitis-derived proteins in a murine model of inflammatory bowel disease is associated with an increase in γδ T cells in large intestinal mucosa

Gut Microbiota As a Modulator of Paneth Cells During Parenteral Nutrition in Mice

The enteric nervous system neuropeptide, bombesin, reverses innate immune impairments during parenteral nutrition

Glucagonlike peptide 2 protects intestinal barrier in severe acute pancreatitis through regulating intestinal epithelial cell proliferation and apoptosis.

Glucagon‐like Peptide 2 Attenuates Intestinal Mucosal Barrier Injury Through the MLCK/pMLC Signaling Pathway in a Piglet Model

Effects of enteral immunonutrition on the maintenance of gut barrier function and immune function in pigs with severe acute pancreatitis

Short-peptide-based enteral nutrition affects rats MDP translocation and protects against gut-lung injury via the PepT1-NOD2-beclin-1 pathway in vivo

The Protective Effect Of Oral Colitis-Derived Proteins In A Murine Model Of Inflammatory Bowel Disease Is Associated With An Increase In Gamma Delta T Cells In Large Intestinal Mucosa

Effects of GLP-2 on Mouse Intestinal Mucosal Proliferation after Ischemia/reperfusion Insult

Effect of Epidermal Growth Factor and Glutamine-Supplemented Toal Parenteral Nutrition on Gut Barrier and Bacterial Translocation

Effects of Short-Peptide-Based Enteral Nutrition on the Intestinal Microcirculation and Mucosal Barrier in Mice with Severe Acute Pancreatitis

Glucagon-like peptide-2-loaded microspheres as treatment for ulcerative colitis in the murine model

Glutamine Improves Innate Immunity and Prevents Bacterial Enteroinvasion During Parenteral Nutrition.

Effects of Glucagon-Like Peptide 2 on the Adaptation of Residual Small Bowel in a Rat Model of Short Bowel Syndrome

N-3 Polyunsaturated Fatty Acid-Enriched Lipid Emulsion Improves Paneth Cell Function Via the IL-22/Stat3 Pathway in a Mouse Model of Total Parenteral Nutrition.